Paula O’Connor

Company: Nurix Therapeutics

Job title: Senior Vice President - Clinical Development

Seminars:

Panel Discussion: How do we Differentiate Degraders from Inhibitors as a Therapeutic Modality? 10:00 am

How do we break away from the inhibitor-based ligands like BRAF? Do we need to? How are we finding new, exciting targets? How do we address the problems with VHL pharmacology such as its larger size?Read more

day: Conference Day Two

Findings from the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B Cell Malignancies 9:00 am

Observe how the activity demonstrated by the BTK degraders, NX-2127 and NX-5948 in phase 1 clinical trials, provide proof of concept for clinical potential of targeted protein degradation Understand that all BTK degraders are not created equally Learn how BTK degradation overcomes mutational liabilities associated with BTK inhibitorsRead more

day: Conference Day Two

Panel Discussion: Assessing Targeted Protein Degradation’s Ability to be Both Selective & Safe 9:45 am

How much progress has been made in identifying and utilising tissue-sparing E3 ligases? Are there more ligases to find? How do we effectively identify them? What does existing off-target safety data tell us about degraders’ behaviour in clinic? Are Molecular Glues a ‘safer’ option? Are there other ‘TACs’ that have potential to be safer due…Read more

day: Conference Day One